Model Medicines Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $8.38M

  • Investors
  • 9

Model Medicines General Information

Description

Developer of an artificial intelligence-driven drug discovery platform designed to accelerate the creation of life-changing drugs. The company offers a pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and communicable diseases, enabling healthcare institutions to develop better medicines tailored to patients' needs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5120 Shoreham Place
  • Suite 285
  • San Diego, CA 92122
  • United States
+1 (619)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 5120 Shoreham Place
  • Suite 285
  • San Diego, CA 92122
  • United States
+1 (619)

Model Medicines Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Model Medicines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Seed Round 21-Oct-2026 $8.38M Completed Generating Revenue
4. Accelerator/Incubator 10-Jun-2025 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2025 Completed Generating Revenue
2. Seed Round 11-Oct-2024 $14.8M $15.5M Completed Generating Revenue
1. Accelerator/Incubator 20-May-2021 $750K $750K Completed Generating Revenue
To view Model Medicines’s complete valuation and funding history, request access »

Model Medicines Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-5
Seed-4
Seed-3
Seed-2 6,969,934 $0.000100 6% $0.56 $0.56 1x $0.56 12.46%
Seed-1 3,593,654 $0.000100 6% $1.14 $1.14 1x $1.14 6.43%
To view Model Medicines’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Model Medicines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an artificial intelligence-driven drug discovery platform designed to accelerate the creation of life-chang
Drug Discovery
San Diego, CA
13 As of 2025

San Mateo, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Model Medicines Competitors (11)

One of Model Medicines’s 11 competitors is BigHat Biosciences, a Venture Capital-Backed company based in San Mateo, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BigHat Biosciences Venture Capital-Backed San Mateo, CA
Relay Therapeutics Formerly VC-backed Cambridge, MA
Numerion Labs Venture Capital-Backed San Francisco, CA
Genesis Molecular AI Venture Capital-Backed San Mateo, CA
InSilico Medicine Cayman Formerly VC-backed Hong Kong, Hong Kong
You’re viewing 5 of 11 competitors. Get the full list »

Model Medicines Patents

Model Medicines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026198473-A1 Computer-implemented systems and methods for compound mutagenicity assessment Pending 17-Mar-2025
US-20260102384-A1 Use of pipendoxifene for treating infections of dna viruses Pending 03-Jul-2024
US-20260199314-A1 Use of pipendoxifene for treating infections of dna viruses Pending 03-Jul-2024
WO-2026011096-A1 Use of pipendoxifene for treating infections of dna viruses Pending 03-Jul-2024
WO-2026011096-A9 Use of pipendoxifene for treating infections of dna viruses Pending 03-Jul-2024 A61K31/454
To view Model Medicines’s complete patent history, request access »

Model Medicines Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Model Medicines Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioTools Innovator Accelerator/Incubator
MedTech Innovator Accelerator/Incubator
8VC Venture Capital Minority
Friedman BioVentures Venture Capital Minority
Irving Investors Growth/Expansion Minority
You’re viewing 5 of 9 investors. Get the full list »

Model Medicines FAQs

  • When was Model Medicines founded?

    Model Medicines was founded in 2019.

  • Where is Model Medicines headquartered?

    Model Medicines is headquartered in San Diego, CA.

  • What is the size of Model Medicines?

    Model Medicines has 13 total employees.

  • What industry is Model Medicines in?

    Model Medicines’s primary industry is Drug Discovery.

  • Is Model Medicines a private or public company?

    Model Medicines is a Private company.

  • What is the current valuation of Model Medicines?

    The current valuation of Model Medicines is .

  • What is Model Medicines’s current revenue?

    The current revenue for Model Medicines is .

  • How much funding has Model Medicines raised over time?

    Model Medicines has raised $23.9M.

  • Who are Model Medicines’s investors?

    BioTools Innovator, MedTech Innovator, 8VC, Friedman BioVentures, and Irving Investors are 5 of 9 investors who have invested in Model Medicines.

  • Who are Model Medicines’s competitors?

    BigHat Biosciences, Relay Therapeutics, Numerion Labs, Genesis Molecular AI, and InSilico Medicine Cayman are some of the 11 competitors of Model Medicines.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process